Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QJT
|
|||
| Former ID |
DNC014899
|
|||
| Drug Name |
GW274150
|
|||
| Synonyms |
GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H17N3O2S
|
|||
| Canonical SMILES |
CC(=NCCSCCC(C(=O)O)N)N
|
|||
| InChI |
1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
|
|||
| InChIKey |
MOLOJNHYNHBPCW-ZETCQYMHSA-N
|
|||
| CAS Number |
CAS 210354-22-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nitric-oxide synthase inducible (NOS2) | Target Info | Modulator | [2], [3] |
| BioCyc | Citrulline-nitric oxide cycle | |||
| KEGG Pathway | Arginine biosynthesis | |||
| Arginine and proline metabolism | ||||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Peroxisome | ||||
| Salmonella infection | ||||
| Pertussis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Pathways in cancer | ||||
| Small cell lung cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Alpha9 beta1 integrin signaling events | ||||
| ATF-2 transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | ROS production in response to bacteria | |||
| Nitric oxide stimulates guanylate cyclase | ||||
| WikiPathways | Type II interferon signaling (IFNG) | |||
| Spinal Cord Injury | ||||
| AGE/RAGE pathway | ||||
| Effects of Nitric Oxide | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00370435) Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA). U.S. National Institutes of Health. | |||
| REF 2 | GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65. | |||
| REF 3 | GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 2005 Jun;145(3):301-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.